Cardioprotective

Icaritin
Catalog No: CFN98527

Icaritin, a potent inhibitor of transcription factor SREBPs, which exhibits a variety of biological activities, such as activation of cancer cell apoptosis and inhibition of growth, hormone regulation, protection against beta amyloid-induced neurotoxicity, and promotion of neuronal and cardiac cellular differentiation. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings.
Cinobufagin
Catalog No: CFN98544

Cinobufagin, a kind of Chinese materia medica with antitumor effect, is widely used in clinical practice, especially in anti-liver cancer, it also has anti-hepatitis B virus activity . Cinobufagin inhibits the proliferation and induces apoptosis, may be related to the mitochondria-mediated pathway and GSK-3β/NF-κB pathway. Cinobufagin can significantly relieve cancer pain in mice and raised their pain threshold, mainly upregulating the expression levels of β -END and μ -OR in the hind paw tumor and adjacent tissue.Cinobufagin and bufalin exhibit cardiotonic and natriuretic activities, they also have inhibitory effects on steroidogenesis of aldosterone and cortisol.
Atractyloside potassium salt
Catalog No: CFN98561

1. Atractyloside potassium salt inhibits oxidative phosphorylation by blocking the transfer of adenosine nucleotides through the mitochondrial membrane.
Fingolimod hydrochloride
Catalog No: CFN90005

Fingolimod hydrochloride is an oral sphingosine-1-phosphate analogue that was approved by the FDA in 2010 for the treatment of relapsing forms of multiple sclerosis (MS). Fingolimod hydrochloride , a pak1 activator, can inhibit astemizole-induced hypertrophy and cytotoxicity in H9c2 cells, suggests that antihistamine-induced cardiac adverse effects are associated with pak1 expression and function.The gels containing 0.50% fingolimod hydrochloride (FNGL) and FNGL 0.50% plus 6% colloidal oatmeal have potential for the treatment of atopic dermatitis (AD).
Arjunolic acid
Catalog No: CFN98690

Arjunolic acid has antioxidant, anti-inflammatory, antinociceptive and anticholinesterasic (AChE and BuChE) activities, it may as promising targets for the development of innovative multi-functional medicines for Alzheimer desease treatment.Arjunolic acid protects cardiac tissues from both extrinsic and intrinsic cell death pathways.Arjunolic acid exhibits better protection against histamine release than against acetylcholine release, anti-asthmatic and anaphylactic activity of it may be possibly due to membrane stabilizing potential and inhibition of antigen induced histamine and acetylcholine release. Arjunolic acid protects cardiac tissues from both extrinsic and intrinsic cell death pathways, it also has antitumor activity.